Published in J Transl Med on October 25, 2014
Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet (2016) 2.48
Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget (2015) 0.85
Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype. Sci Rep (2015) 0.77
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clin Cancer Res (2016) 0.76
Androgen Receptor Signaling in Salivary Gland Cancer. Cancers (Basel) (2017) 0.75
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J Mol Sci (2017) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Sequencing technologies - the next generation. Nat Rev Genet (2009) 40.57
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn (2013) 3.36
Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A (2007) 3.15
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol (2003) 2.38
[Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd (1968) 2.08
Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer (1996) 1.95
Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer (2005) 1.94
PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat (2005) 1.89
Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol (2006) 1.88
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer (2007) 1.79
PIK3CA mutation and amplification in human lung cancer. Pathol Int (2007) 1.55
Update on selected salivary gland neoplasms. Arch Pathol Lab Med (2009) 1.41
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol (2008) 1.32
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol (2008) 1.31
Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck (2007) 1.30
Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res (2010) 1.26
HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res (2004) 1.25
KRAS mutations in lung cancer. Clin Lung Cancer (2012) 1.22
Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck (2008) 1.18
Salivary duct carcinoma: what is already known, and can we improve survival? J Laryngol Otol (2012) 1.18
Biology and management of salivary gland cancers. Semin Radiat Oncol (2012) 1.09
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res (2012) 1.06
Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol (2011) 1.06
Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer (2012) 1.02
Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology (2011) 0.98
PIK3CA mutations and PTEN loss in salivary duct carcinomas. Am J Surg Pathol (2013) 0.97
Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Appl Immunohistochem Mol Morphol (2008) 0.95
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer (2012) 0.93
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer (2008) 0.92
Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol (2014) 0.89
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck (2013) 0.87
Concern Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol (2012) 0.86
Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck (2015) 0.83
Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma. Biomed Res Int (2014) 0.81
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol (2012) 3.90
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2012) 3.89
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol (2013) 3.63
Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol (2005) 2.90
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 2.89
Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol (2003) 2.64
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.62
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res (2010) 2.48
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol (2012) 2.44
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys (2005) 2.19
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol (2003) 2.17
Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. J Thorac Oncol (2015) 2.17
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol (2009) 2.13
Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res (2009) 2.12
Association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. Head Neck (2014) 2.10
Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol (2004) 2.02
Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol (2013) 1.93
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol (2012) 1.76
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood (2007) 1.74
Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med (2006) 1.72
Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology (2013) 1.71
Primary pulmonary non-Hodgkin's lymphoma. Jpn J Clin Oncol (2004) 1.70
Extent of prophylactic lymph node dissection in the central neck area of the patients with papillary thyroid carcinoma: comparison of limited versus comprehensive lymph node dissection in a 2-year safety study. Ann Surg Oncol (2008) 1.66
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer (2009) 1.65
Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. Leuk Res (2006) 1.60
The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. Lung Cancer (2013) 1.58
A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer (2006) 1.56
Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma (2007) 1.53
Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat (2009) 1.51
Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol (2009) 1.50
Clinical features and treatment outcomes of intravascular large B-cell lymphoma: a single-center experience in Korea. Acta Haematol (2013) 1.50
Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol (2013) 1.50
Buccinator myomucosal flap for reconstruction of glossectomy defects. Otolaryngol Head Neck Surg (2013) 1.48
Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol (2010) 1.47
Dry pleural dissemination in non-small cell lung cancer: prognostic and diagnostic implications. Radiology (2011) 1.46
Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery (2010) 1.45
Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP. Acta Haematol (2013) 1.45
Outcome and predictors of mortality in patients requiring invasive mechanical ventilation due to acute respiratory failure while undergoing ambulatory chemotherapy for solid cancers. Support Care Cancer (2013) 1.44
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer (2007) 1.42
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. J Thorac Oncol (2010) 1.41
Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol (2013) 1.40
Pharyngo-colostomy with supraglottic partial laryngectomy in caustic oropharyngeal stricture. Ann Thorac Surg (2006) 1.39
[Microsatellite instability in gastric B-cell lymphoma]. Korean J Gastroenterol (2006) 1.39
The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther (2012) 1.37
Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck (2012) 1.30
Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol (2011) 1.30
Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer (2005) 1.28
High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol (2012) 1.26
Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol (2005) 1.23
A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol (2012) 1.23
Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf) (2006) 1.22
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer (2012) 1.21
Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck (2007) 1.19
Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol (2010) 1.14
Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2013) 1.14
Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res (2010) 1.14
EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PLoS One (2013) 1.13
Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant (2008) 1.13